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Very early neuroglial changes have been observed to precede major vascular changes in the retina of diabetic patients and animal
models. We investigated the sequence of these neuroglial changes further, in mice with alloxan-induced diabetes. Diabetes was induced
by a single injection of Alloxan into C57/Bl6 mice, which subsequently received daily insulin injections. Diabetic and control animals
were weighed and their blood glucose levels were determined weekly. Electroretinographic recordings and scanner laser ophthalmoscope
(SLO) examinations were carried out 15 days, one month and three months after the onset of diabetes. Diabetes induction was conﬁrmed
by the presence of glucose in the urine, a tripling of blood glucose level, weight loss and an increase in glycated haemoglobin levels. Three
months after diabetes onset, the electroretinogram b/a wave amplitude ratio was decreased at the highest light intensities and oscillatory
potentials were delayed. The retinal fundus and vessels remained unchanged. No cell apoptosis was detected in vertical and horizontal
sections of the retina by TUNEL or immunocytochemistry for the active caspase 3. No increase in GFAP-immunostaining indicative of a
glial reaction was observed in Mu¨ller glial cells. By contrast, changes in the morphology of microglial cells were observed, with marked
shortening of the dendrites. Thus, the microglial reaction occurs very early in progression to diabetic retinopathy, at about the same time
as early electroretinographic modiﬁcations. The absence of apoptotic cells, contrasting with previous results in mice with streptozotocin-
induced diabetes, is consistent with insulin neuroprotection.
 2006 Elsevier Ltd. All rights reserved.
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Diabetic retinopathy (DR) is a common complication of
diabetes that can lead to legally recognised blindness. This
condition has been extensively studied but its pathophysi-
ology remains poorly understood. DR is classically consid-
ered to be a microangiopathy because microaneurysms and0042-6989/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.visres.2006.11.017
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E-mail address: picaud@st-antoine.inserm.fr (S. Picaud).the proliferation of new vessels are observed, together with
a breakdown of the blood retinal barrier (BRB). The BRB
is located at the junctions between endothelial cells in the
capillaries. Its normal function is regulating the movement
of molecules into and out of the retina. BRB breakdown is
routinely identiﬁed in patients with DR in clinical practice,
by ﬂuorescein angiography, in which the abnormal leakage
of ﬂuorescein from the capillaries is observed (Davis,
1992). These vascular changes may result from biochemical
disorders, such as activation of the polyol and b-kinase
pathways, and the production of glycated products and
D. Gaucher et al. / Vision Research 47 (2007) 612–623 613reactive oxidative species due to an increase in serum glu-
cose concentration (Ciulla, Amador, & Zinman, 2003).
Retinal cell degeneration and blindness may result from
these vascular changes and subsequent retinal ischaemia.
However, several recent studies have suggested that neu-
rodegenerative events may precede the vascular changes.
Indeed, changes in retinal function have been reported in
humans and animals before the detection of retinal vascu-
lar lesion in the form of BRB rupture or microaneurysms.
In diabetic patients, colour vision and contrast sensitivity
may deteriorate without detectable clinical symptoms of
DR (Ewing, Deary, Strachan, & Frier, 1998). Electroretin-
ograms (ERG) show very early changes in oscillatory
potentials (OP) and changes are also observed on multifo-
cal ERG (Bresnick & Palta, 1987; Fortune, Schneck, &
Adams, 1999; Tzekov & Arden, 1999; Yoshida, Kojima,
Ogasawara, & Ishiko, 1991). Histologically, neuronal
apoptosis has been observed in ganglion cells before any
change could be detected in the retinal vascular system
(Barber et al., 1998). This degeneration is associated with
glial reactions in Mu¨ller cells, generally observed following
the appearance of retinal lesions (Abu-El-Asrar, Dralands,
Missotten, Al-Jadaan, & Geboes, 2004).
Proliferative diabetic retinopathy has rarely been
described in diabetic animal models, although neovascular-
isation has been described in a few transgenic animals (Lai
et al., 2005; Ruberte et al., 2004; Yamada, Yamada, Higu-
chi, & Matsumura, 2005). Changes of various magnitudes
have been reported on ERG: increases in OP latencies,
and decreases in OP amplitudes, a- and b-waves (Ewing
et al., 1998; Hancock & Kraft, 2004; Li, Zemel, Miller, &
Perlman, 2002; Lowitt, Malone, Salem, Kozak, & Orfalian,
1993; Sakai, Tani, Shirasawa, Shirao, & Kawasaki, 1995).
Neuronal apoptosis has been described in the ganglion cell
layer in various diabetic animal models (Agardh, Bruun, &
Agardh, 2001; Barber et al., 1998; Martin, Roon, Van Ells,
Ganapathy, & Smith, 2004; Ning et al., 2004). Neuronal
degeneration has also been detected in other retinal layers
in some models (Agardh et al., 2001; Ning et al., 2004).
This degenerative process has been attributed to the glial
reaction of Mu¨ller cells, as in diabetic humans (Agardh
et al., 2001; Asnaghi, Gerhardinger, Hoehn, Adeboje, &
Lorenzi, 2003; Li et al., 2002; Lieth et al., 1998; Rungger-
Brandle, Dosso, & Leuenberger, 2000), or to microglial cell
activation in some cases (Barber et al., 2005; Rungger-
Brandle et al., 2000; Zeng, Ng, & Ling, 2000). However,
these neuroglial reactions are not observed in all animal
models of DR (Agardh et al., 2001; Asnaghi et al., 2003;
Barber et al., 2005, 1998; Li et al., 2002; Lieth et al.,
1998; Martin et al., 2004; Ning et al., 2004; Rungger-Bran-
dle et al., 2000). In particular, neuronal apoptosis was ﬁrst
described in rats with streptozotocin-induced diabetes
(Barber et al., 1998), but is not systematically observed in
mice with streptozotocin-induced diabetes (Asnaghi et al.,
2003; Martin et al., 2004).
In this study, we assessed BRB permeability and retinal
cell activity in vivo, in mice with alloxan-induced diabetes,a classical animal model of diabetes in which DR has not
yet been investigated. Alloxan and STZ are both diabeto-
genic agents with cytotoxic eﬀects on pancreatic b-cells
resulting from the production of reactive oxygen species.
Alloxan generates oxidative stress conditions, with a
simultaneous massive increase in cytosolic calcium
concentration, whereas STZ induces DNA alkylation
(Szkudelski, 2001). At the ﬁrst sign of functional changes
in Alloxan-induced mice, we looked for neuroglial reac-
tions on vertical and horizontal retinal sections. We
report here that changes in microglial cell morphology
are the ﬁrst detectable cellular modiﬁcations occurring
in mice with alloxan-induced diabetes, apparently preced-
ing neuronal apoptosis and increases in blood barrier
permeability in this model.
2. Materials and methods
2.1. Animals and experimental diabetes induction
Weused twentyC57/Bl6malemice,whichwere handled according to the
principles of the ARVO statement for the use of animals in ophthalmic and
vision research. The mice were maintained on a standard diet, with water
supplied ad libitum, under a 12-h light/12-hdark cycle.Diabeteswas induced
by a single injection of Alloxan (75 mg/kg) into the tail vein, as described by
Larger, Becourt, Bach, and Boitard (1995). Animals were 10 weeks old and
weighed around 25 g at the time of injection. Nine mice received injections,
the others being used as controls. Diabetic mice received a daily subcutane-
ous injection of three international units of insulin (Umuline Zinc, Lilly
Laboratories, France), in the morning (9 a.m.). Insulin was administered
to keep the animals alive during the study period, because a few mice with
alloxan-induced diabetes had previously been reared without treatment,
but they had survived for no more than two weeks.
2.2. Glucose levels
Animals were weighed once per week. We checked for the presence of
glucose in the urine twice during the ﬁrst week after injection (urine glu-
cose test strips, Roche Diagnostics, France). Blood glucose levels were
determined once per week for the three months of the study and just
before the mice were killed. Blood samples were obtained from the lateral
vein of the tail (blood glucose meter and OneTouch Ultra test strips, Life-
scan, France).
2.3. Glycated haemoglobin determinations
Just before the animals were killed, blood samples from the right retro-
orbital venous sinus were collected into calcium ethylenediaminotetra-ace-
tic acid (EDTA). Glycated haemoglobin levels were determined automat-
ically, by high-performance liquid chromatography, as described by Ou
and Rognerud (1993). Brieﬂy, we diluted 10 lL of blood in a hypotonic
cell lysis solution (0.1% Brij, Sigma). Haemoglobins were then separated
on a porous silica column containing polyaspartic acid (Poly CatA, Poly
LC, Houston, USA). Various ionic gradients were obtained by mixing
two buﬀer solutions (20 mM bis-Tris, 2 nM KCN, pH 5.8 and 20 mM
bis-Tris, 2 nM KCN, 75 mM trisodium citrate, pH 5.8). These gradients
were used to separate the haemoglobins, which were detected by spectros-
copy at 418 nm.
2.4. Ocular examination, funduscopy and ﬂuorescein angiographs
Fundus examinations and angiographs were performed on all mice, 15
days, 1 month and 3 months after the pharmacological induction of diabe-
tes. Cornea, eye lens and fundus were examined with a biomicroscope
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graphs of the eye fundus and angiographs were obtained with a scanning
laser ophthalmoscope (SLO) (HRA, Heidelberg, Germany). Retinal angi-
ography was carried out after the intraperitoneal injection of 25% ﬂuores-
cein in 0.9% NaCl. Mouse pupils were dilated by the ocular instillation of
tropicamide eye drops (0.5%). Fundus images were obtained for each eye
before, 1 and 5 min after the ﬂuorescein injection.2.5. Retinal electrophysiology
Electroretinograms (ERG) were obtained from all animals, 15 days,
1 month and 3 months after diabetes induction. Animals were acclimatised
to the dark for 12 h before the recording. They were anaesthetised by intra-
peritoneal injection (10 ll/g) of a mixture of ketamine (10%) and xylazine
(7.5%) in 0.9%NaCl.Corneaswere anaesthetisedwith oxybuprocaine chlor-
hydrate (0.4%) and the pupil was dilated with tropicamide (0.5%). Each ani-
mal was placed on a heating pad, and the eyelids were retracted to keep the
eye open during the recording. A gold electrode was placed on the cornea
with a drop of methylcellulose and the neutral and reference electrodes were
placed on the tail and headof the animal, respectively. Light stimulationwas
delivered via a Ganzfeld light source, with ﬂash intensities from 104 to
25 cd s m2. Responses were ampliﬁed, high- and low-pass-ﬁltered
(1–300 Hz) and digitised (Multiliner Vision, Toennies/Jaeger, Hoechberg,
Germany). Oscillatory potentials (OP) were isolated for a light stimulus of
3 cd s m2 by ﬁltering the responses with a high-pass ﬁlter at 100 Hz and a
low-pass ﬁlter at 300 Hz. The amplitudes and latencies of the ERG a- and
b-waves were measured at the maximum negative and positive peaks of
the recordings with respect to the baseline before stimulation. As recom-
mended by the ISCEV (International Society for Clinical Electrophysiology
of Vision), OP amplitudes weremeasured from the negative peak to the next
positive peak whereas OP latencies were measured at the positive peaks.We
summed OP amplitudes (Sampl) and latencies (Slat) for the ﬁrst 5 OP
because these parameters provide information about inner retinal cell func-
tion (amacrine cells) and were found to be modiﬁed in other diabetic animal
models (Hancock &Kraft, 2004; Hotta et al., 1997) and in diabetic patients
(Bresnick & Palta, 1987; Yoshida et al., 1991).2.6. Cell labelling
Animals were killed three months after diabetes induction. The left eye
of each animal was enucleated for the labelling of cells on vertical retinal
sections, whereas the right eye was dissected for the preparation of a ﬂat-
mounted retina. Eye cups and retina were ﬁxed overnight in 4% parafor-
maldehyde (PAF) at 4 C. A few ﬂat-mounted retina (from one control
and two diabetic mice) were embedded in orbithine carbamyl transferase
(OCT) medium and cut into 40 lm-thick horizontal retinal sections. Entire
retinas were stained for GFAP as described by Rungger-Brandle et al.
(2000), by incubation with the polyclonal anti-GFAP antibody (2.5 days,
4 C), followed by washing and incubation with the secondary antibody
(1.5 days, 4 C). Retinae were incubated with antibodies in a permeabilis-
ing solution containing 1% Triton X-100 in phosphate-buﬀered saline
(PBS). Vertical retinal sections were cut from eye cups embedded in
OCT medium after cryoprotection in various sucrose solutions. Vertical
sections were permeabilised by incubation for 1 h at 37 C with 0.5% Tri-
ton X-100 in a solution containing 1% bovine serum albumin (BSA) and
0.05% Tween 20 in PBS. Sections were incubated overnight at 4 C with
primary antibodies diluted in permeabilising solution. The primary anti-
bodies used were rabbit anti-GFAP (1/200, Dako, USA) and rabbit
anti-phosphotyrosine (1/500, Zymed, USA) antibodies. Sections were
washed several times in PBS and then incubated for 1 h at room temper-
ature with the secondary antibody in permeabilising solution supplement-
ed with 4 0,6-diamidino-2-phenylindole (DAPI) for nuclear staining (1/500,
Sigma). The secondary antibody used was an Alexa ﬂuor 488- or 594-con-
jugated goat anti-rabbit antibody (1/500, Molecular Probes, USA).
Neuronal apoptosis was investigated by terminal UTP nick-end label-
ling (TUNEL) coupled with ﬂuorescein (TUNEL-FITC detection kit;
Roche Diagnostics, France). Vertical sections (5–8 per retina) and hori-zontal sections (6 per eye) of retina were permeabilised by incubation
for 5 min with 0.1% Triton X-100 in PBS. They were then stained by incu-
bation with 4 0,6-diamidino-2-phenylindole (DAPI) for 5 min, and incubat-
ed with the kit solution for 1 h at 37 C.
2.7. Cell quantiﬁcation
All specimens were viewed with a ﬂuorescence microscope (Leica
DM5000B, Germany) equipped with a digital camera (Coolsnap fx, Pho-
tometrix, Roper Scientiﬁc, USA) linked to a computer running image
analysis software (Metavue 6.2R4, Universal Imaging Corp, USA). Digi-
tal images were acquired using identical settings in all cases. Microglial
cells were counted and the length of their dendrites was determined on
two diﬀerent retinal sections including the optic nerve for each animal.
Dendrites were measured with Metavue software.
2.8. Statistical analysis
Statistical comparisons were made by unpaired t-tests when possible,
and by non-parametric Mann–Whitney U-tests otherwise. Statistical anal-
ysis was carried out with Statview 5.0 (SAS Institute Inc., USA). Signiﬁ-
cance tests were performed with (p = 0.05) taken as the threshold for
signiﬁcance.
3. Results
3.1. Diabetes follow-up
Following the injection of alloxan, the induction of dia-
betes was conﬁrmed based on weight stagnation, polydip-
sia and polyuria in mice (Fig. 1). The day after alloxan
injection, glucose was detected in the urine and blood glu-
cose levels at least doubled in injected mice. The blood glu-
cose levels ranged from 5.89 to 13.68 mM in control
animals and from 19.68 to 33.36 mM in diabetic mice.
Blood glucose levels remained three times higher in diabetic
than in control animals throughout the three-month study
period and the weight gain of these animals was reduced by
approximately 50% (Fig. 1). Three months after the diabe-
tes induction, glycated haemoglobin levels were 2.72%
(±0.06, n = 9, SEM) in control mice and 6.54% (±0.82,
n = 5, SEM) in diabetic animals. Thus, despite the contin-
uous insulin treatment, the diabetic mice displayed chronic
hyperglycaemia.
3.2. No vascular lesion
We evaluated the integrity of the blood retinal barrier,
by examining diabetic and control animals by ﬂuorescein
angiography with a scanning laser ophthalmoscope. No
haemorrhage, microaneurism or proliferation of new ves-
sels was detected. Fig. 2 shows ﬂuorescein angiograms for
control and diabetic animals. We assessed the diﬀusion of
this dye out of the capillary network by analysing angio-
grams taken at diﬀerent time points after ﬂuorescein injec-
tion, because ﬂuorescein diﬀusion into the retinal tissue
provide evidence for the breakdown of the internal BRB
(Rakoczy et al., 2003). However, no ﬂuorescein diﬀusion
into the retinal tissue was detected and the morphology
and density of the retinal capillary network remained
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Fig. 1. Blood glucose concentration (A) and animal weight (B) in control mice (n = 9 at study ending) and mice with alloxan-induced diabetes (n = 5 at the
end of the study) over a 3-month period. Each graph shows changes in these parameters for the control (squares) and diabetic (triangles) mice during the 3
months of the experiment. The induction of diabetes was demonstrated by the increase in blood glucose concentration and the stabilisation of body weight.
(Means and the standard errors of means (SEM) are indicated.)
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entire study (Fig. 2). These observations suggest that
the BRB was not ruptured during the three months of
the experiment in mice with alloxan-induced diabetes.3.3. Functional changes
We investigated the possible eﬀects of diabetes on neuro-
nal cell activity in our model, by recording electroretino-
grams at various time points after the induction of
diabetes. We checked that the cornea and ocular lens were
clear before each recording, because cataracts are often
observed in diabetic animals. No statistically signiﬁcant
change in ERG was detected one month after diabetes
induction. After three months, the amplitudes and latencies
of the ERG a- and b-waves remained unchanged, but a sig-
niﬁcant decrease in the b-wave/a-wave amplitude ratio (b/
a) was observed for light intensities of 10 and 25 cd s m2 (t
test, p = 0.014 and 0.018 respectively). The sum of OP
latencies was also higher in diabetic mice (n = 5, t test,
p = 0.034) than in control mice (n = 9) (Fig. 3, Table 1).
These observations suggest that three months of diabetes
led to changes in neuronal cell activity.3.4. Absence of neural apoptosis
In diabetic animal models, neuronal apoptosis has been
reported as early as one month after diabetes induction
(Barber et al., 1998). We therefore investigated the distribu-
tion of apoptotic cells in vertical and horizontal retinal sec-
tions, using TUNEL and cleaved caspase 3 detection. Even
three months after the induction of diabetes, no apoptotic
cells were detected with either of the cell death markers.
For example, Fig. 4A and B shows the absence of TUNEL
staining on vertical retinal sections from control animals
and diabetic mice three months after diabetes induction.The eﬃcacy of our labelling technique was checked by
staining retinal sections from an rd (retinal degeneration)
mouse by TUNEL. As expected, in this animal presenting
photoreceptor degeneration, several TUNEL-positive
apoptotic cells were detected in the outer nuclear layer
(Fig. 4C, arrows). TUNEL was also performed on horizon-
tal sections, because only a few retinal ganglion cells are
present in vertical sections and these cells have been report-
ed to undergo degeneration early in progression to DR in
diabetic patients and in rats with streptozotocin-induced
diabetes (Barber et al., 1998). No TUNEL-positive cells
were detected on horizontal sections containing large num-
bers of retinal ganglion cells (data not shown). Despite the
observed change in retinal cell activity, no retinal cell apop-
tosis was detected three months after the induction of dia-
betes with alloxan.3.5. Absence of macroglial reaction
As a glial reaction has been described in diabetic animal
models and human patients (Agardh et al., 2001; Hancock
& Kraft, 2004; Li et al., 2002; Lieth et al., 1998; Rungger-
Brandle et al., 2000; Sakai et al., 1995), we labelled vertical
retinal sections with an anti-GFAP antibody. In control
animals, this antibody labelled astrocytes in the ganglion
cell layer (Fig. 4D). Three months after the induction of
diabetes, no abnormal glial reaction was observed in dia-
betic mouse retina. A few Mu¨ller cells were stained in the
inner retina (Fig. 4E, arrow), but such staining was also
observed in a few control retinas. We stained a retinal sec-
tion from an rd mouse with the anti-GFAP antibody, to
obtain information about the nature of reactive glial cells.
In this mouse, the anti-GFAP antibody strongly labelled
many glial cell processes extending from the outer plexi-
form layer to the inner limiting membrane (Fig. 4F, arrow).
We investigated possible changes in morphology in these
Fig. 2. Absence of vascular changes in mice with alloxan-induced diabetes. Retinal angiographies showing the superﬁcial vessels (A–C) and deep capillary
networks (D–E) in a control animal (A and D) (n = 5) and in mice with alloxan-induced diabetes (n = 5) (B, C and E) at the end of the 3-month study
period. These images show normally perfused retinal vessels, with no new vessels and no increase in vascular permeability.
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In diabetic animals, the morphology of the GFAP-positive
astrocytes was normal on ﬂat-mounted retina (Fig. 4G and
H). This examination demonstrated the absence of a
macroglial reaction in mice with alloxan-induced diabetes,
three months after diabetes induction.3.6. Microglial changes
Microglial cells in the ganglion cell layer, the inner
plexiform layer and the inner nuclear layer were
visualised by speciﬁc staining with an anti-phosphotyrosine
antibody (Fig. 5). The speciﬁcity of immunolabelling was
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Fig. 3. Functional changes were recorded in mice with alloxan-induced diabetes, 15 days (A and E), 1 month (B and F) and 3 months (C, D, G and H)
after the induction of diabetes. (A–C) The ratio of B and A waves on the electroretinogram (ERG) was signiﬁcantly lower in diabetic animals than in
control animals for the strongest stimulus, after 3 months of diabetes (C). (D) Representative recording of scotopic ERG responses to a 10 cd s/m2 light
stimulus (arrowhead), showing the decrease in b/a amplitude ratio in a diabetic mouse (dark line) 3 months after the onset of diabetes, and comparison
with a control mouse (grey line). (E–G) Oscillatory potentials (OP) remained unchanged in terms of summed amplitudes (Sampl) at all time points whereas
the sum of their latencies (Slat) was signiﬁcantly higher in diabetic than in control mice after three months (G). (H) Representative recording of OP to a
3 cd s/m2 light stimulus (arrowhead), showing the longer OP latency in a diabetic mouse (dark line) 3 months after the onset of diabetes than in a contro
mouse (grey line). (Means and standard errors of the means (SEM) are indicated in the bar graphs, *signiﬁcant diﬀerence, t test, p < 0.05).
D. Gaucher et al. / Vision Research 47 (2007) 612–623 617l
Table 1
Changes in electroretinogram measurements in diabetic mice
Time (months) a wave lV ± SD b wave lV ± SD Ratio b/a ±SD Sampl Ops lV ± SD Slat Ops ms ± SD
Stimulus (cd s m2) 10 10 10 3 3
Control mice 0.5 182.1 ± 48.5 447.5 ± 139.2 2.4 ± 0.4 781.5 ± 250.2 159.6 ± 25.1
Diabetic mice 0.5 216.7 ± 71 479.3 ± 217 2 ± 0.3 726.6 ± 230.5 174.7 ± 34.6
Control mice 1 228.4 ± 39.7 448.3 ± 137 1.9 ± 0.4 647.8 ± 193.8 174.4 ± 15.3
Diabetic mice 1 189.9 ± 47.7 368.1 ± 65.9 2 ± 0.5 566.1 ± 79.7 183.7 ± 9.4
Control mice 3 163.6 ± 36.1 365 ± 58.6 2.2 ± 0.3 686.2 ± 139.4 171.9 ± 10.9
Diabetic mice 3 207.7 ± 63.9 368 ± 99.1 1.8 ± 0.3* 611.4 ± 196.7 187.2 ± 12.6*
Mean amplitudes of a and b waves, mean b/a amplitude ratio and mean of the summed oscillatory potential (OP) amplitudes (Sampl) and latencies (Slat)
in mouse retina, 15 days, 1 month and 3 months after diabetes induction.
* Signiﬁcant diﬀerence, t test, p < 0.05.
Fig. 4. Absence of macroglial reaction and apoptosis in animals with alloxan-induced diabetes, after 3 months. (A–C) No TUNEL-positive apoptotic cells
were detected in the diabetic (B) and control (A) mice, whereas such cells were detected in rd mice (C). (D–F) GFAP expression in retinal sections of
diabetic mice (E) was no stronger than that in control animals (D), whereas stronger staining was observed with sections from rd mice (F). (G and H)
GFAP-positive astrocytes displayed no morphological alterations on ﬂat-mounted retinas from control animals (G) and diabetic mice (H). Scale bars
represent 10 lm. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; ONL, outer nuclear layer.
618 D. Gaucher et al. / Vision Research 47 (2007) 612–623demonstrated on a vertical section of retina from a mouse
strain in which the gene encoding the chemokine receptor
CX3CR1 was replaced by the gene encoding enhanced
green ﬂuorescent protein (EGFP) (Jung et al., 2000). In
these animals, brain and retinal microglial cells, whichwould normally express CX3CR1, become EGFP-positive.
These EGFP-positive retinal microglial cells were
immunolabelled with the anti-phosphotyrosine antibody
(Fig. 5A–C). In vertical retinal sections, microglial cell
nuclei and processes were clearly identiﬁed and quantiﬁed
Fig. 5. Microglial changes in mice with alloxan-induced diabetes. (A–C) Microglial cell immunolabelling with the anti-phosphotyrosine antibody in mice.
A microglial cell expressing green ﬂuorescent protein (GFP) (A) is immunolabelled with the anti-phosphotyrosine antibody (B) in a CX3CR1-deﬁcient
mouse, as indicated on the merged image (C). (D, E, G and H) Retinal sections stained with the anti-phosphotyrosine antibody showing immunopositive
microglial cells in control mice (D and G) and in mice with alloxan-induced diabetes, after 3 months (E and H). Microglial cells appeared to have larger
cell soma and shorter cell processes in diabetic animals (E and H) than in control mice (D and G). In (D and E), the nuclear dye DAPI was used to detect
the various nuclear layers. (F) Quantiﬁcation of phosphotyrosine-immunopositive microglial cells in diﬀerent retinal layers of control animals and mice
with alloxan-induced diabetes, after 3 months. Microglial cell nuclei were quantiﬁed in the GCL, IPL and INL. No statistically signiﬁcant diﬀerences in the
number of microglial cells were found between controls and diabetic animals (p > 0.05) (B). (I) Quantiﬁcation of the cumulative length of microglial cell
dendrites (arrows in D and E), measured on complete retinal sections in control (G) and diabetic animals (H). Dendrites were signiﬁcantly shorter in the
diabetic mice (*p = 0.01). GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer. Scale bars represent 10 lm (A–H) and 25 lm (G
and H). (Means and the standard errors of means (SEM) are indicated in the graph.)
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(IPL) and ganglion cell layer (GCL). Diabetic and control
animals had similar numbers of phosphotyrosine-positive
microglial cells (Fig. 5F), but the cell bodies of these cells
seemed to be larger in diabetic animals, with thicker prox-
imal processes and shorter dendrites (Fig. 5D–E). The
cumulative length of microglial dendrites was determined
on complete sections including the optic nerve (Fig. 5G
and H), and was found to diﬀer signiﬁcantly between dia-
betic and control animals (Fig. 5I, t test, p = 0.01). As
microglial cells are known to display a change in morphol-
ogy, including dendrite contraction, in the early stages of
activation, these observations suggest that microglial cells
were activated three months after the onset of diabetes in
mice with alloxan-induced diabetes.
4. Discussion
This study on mice with alloxan-induced diabetes
showed that changes to oscillatory potentials and ERG
b/a amplitude wave ratio ﬁrst became detectable three
months after the onset of diabetes. No change in blood ves-
sel permeability was detected in vivo by ﬂuorescein angiog-
raphy carried out with a scanning laser ophthalmoscope.
No ganglion cell apoptosis or macroglial reaction was
detected, but changes in microglial cells were observed,
with a decrease in the length of microglial cell processes,
which is known to occur early in microglial activation.
Insulin treatment was insuﬃcient to regulate blood glucose
levels, but may have protected against neuronal apoptosis.
4.1. The sequence of events in the retina following the
induction of diabetes
In diabetic patients, OPs provide the ﬁrst sign of retinal
alteration, as their amplitude decreases and their latency
increases even at a pre-retinopathy stage characterised by
an absence of detectable vascular changes on funduscopy
(Shirao & Kawasaki, 1998). Other ERG changes have also
been observed, including a change in ERG pattern (Caputo
et al., 1990), scotopic and photopic b-wave alterations
(Holopigian, Seiple, Lorenzo, & Carr, 1992) and a speciﬁc
reduction of S-cone ERG (Yamamoto, Kamiyama, Nitta,
Yamada, & Hayasaka, 1996). Changes in OP latencies
and amplitudes have also been described in various animal
models (Li et al., 2002; Sakai et al., 1995; Segawa, Hirata,
Fujimori, & Okada, 1988). In rats with STZ-induced diabe-
tes, these OP changes are detected as early as two weeks
after diabetes induction (Li et al., 2002; Sakai et al.,
1995). Other changes in ERG responses, such decreases
in b-wave magnitude, have also been observed in these ani-
mal models (Li et al., 2002). In our mice with alloxan-in-
duced diabetes, no signiﬁcant changes were detected in
ERG a- and b-waves, but changes in the b/a wave ampli-
tude ratio were statistically signiﬁcant three months after
the onset of diabetes. Indeed, this ratio could be used to
normalise ERG measurements between mice. However,the variability of this measure in control animals at the var-
ious time points studied (Table 1) limits the value of the dif-
ference observed at three months. By contrast, OP latencies
steadily increased over the ﬁrst three months, providing
evidence for the importance of the statistically signiﬁcant
increase in OP latency reported at 3 months. Similar
increases in OP latency have been reported for streptozoto-
cin-treated rats after ﬁve weeks of diabetes (Li et al., 2002;
Sakai et al., 1995) and in diabetic patients with and without
retinopathy (Bresnick & Palta, 1987; Yoshida et al., 1991).
The presence of such increases in OP latency in diabetic
patients without retinopathy and in our alloxan-treated
mice is consistent with the notion that this change is a very
early marker of diabetes-induced retinal changes. These
ERG changes are consistent with the suggested changes
in the GABA-ergic system or with dysfunction of the inner
retinal vasculature (Hanitzsch, Kuppers, & Flade, 2004;
Ishikawa, Ishiguro, & Tamai, 1996a; Ishikawa, Ishiguro,
& Tamai, 1996b; Shirao & Kawasaki, 1998; Wachtmeister,
1998).
In diabetic patients and animals, retinal cell apoptosis in
the various retinal layers has been described as an early
event, preceding vascular alterations (Asnaghi et al.,
2003; Barber et al., 1998; Martin et al., 2004; Ning et al.,
2004; Park et al., 2003). In animal models, this cell death,
detected by both TUNEL and immunolabelling for active
caspase-3, has generally been detected in the ganglion cell
layer one month after the induction of diabetes, but it
may also occur earlier, after as little as two weeks (Ning
et al., 2004). Retinal cell death has also been observed in
the photoreceptor layer and the inner nuclear layer, but
during a later phase of the disease (Ning et al., 2004; Park
et al., 2003). In mice with STZ-induced diabetes, Asnaghi
reported no increase in the number of apoptotic cells after
10 and 24 weeks of diabetes, whereas Martin reported such
retinal apoptosis at 2, 6 and 12 weeks (Asnaghi et al., 2003;
Martin et al., 2004). In mice with alloxan-induced diabetes,
no cell death was detected in any cell layer after three
months of diabetes, even if horizontal sections were used
so that large numbers of ganglion cells could be studied
at a glance. These results indicate that the early ERG
changes are not a consequence of retinal cell death.
Several studies have reported that ERG modiﬁcations
and ganglion cell apoptosis are followed by a glial reaction
in diabetic patients and animal models (Agardh et al., 2001;
Hancock & Kraft, 2004; Li et al., 2002; Lieth et al., 1998;
Rungger-Brandle et al., 2000; Sakai et al., 1995). In rats
with STZ-induced diabetes, the glial reaction appeared
after 6–15 weeks of diabetes (Li et al., 2002; Lieth et al.,
1998). In mice with alloxan-induced diabetes, ERG modiﬁ-
cations appeared only after 3 months of diabetes and no
glial reaction, as assessed by GFAP labelling, could be
detected. Further studies should determine whether this gli-
al reaction and ganglion cell death occur even later in this
model.
Microglial cells are also activated in rats with STZ-in-
duced diabetes (Rungger-Brandle et al., 2000; Zeng et al.,
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this activation is demonstrated by the hypertrophy of
microglial cells after 1 month of diabetes, the number of
cells increased after 4 months these cells migrated into
the outer nuclear layer after 14 to 16 months (Zeng et al.,
2000). Rungger-Brandle et al. (2000) detected an increase
in the number of microglial cells as early as 1 month after
diabetes induction, before the increase in GFAP expres-
sion. Barber found swollen and retracted microglial cell
processes in Ins2 Atika mice (Barber et al., 2005), as
observed in our mice with alloxan-induced diabetes. No
increase in the number of retinal microglial cells was detect-
ed in mice with alloxan-induced diabetes, but we did
observe a change in the morphology of these cells, as
described above. These changes in the morphology of
microglial cells are known to be associated with the
microglial ‘‘alert’’ activation stage (Raivich et al., 1999).
Our ﬁndings suggest that microglial cells may be activated
in the diabetic mouse retina before ganglion cell death and
the subsequent macroglial reaction. These observations are
consistent with ﬁndings for Ins2 Atika mice showing
microglial activation but no increase in GFAP expression
by Mu¨ller cells (Barber et al., 2005). Microglial cell activa-
tion was correlated with the ERG changes observed in our
study, and may trigger the ganglion cell death reported in
other diabetic animal models. This sequence of events is
supported by the neuroprotection conferred by the anti-in-
ﬂammatory drug, minocycline, in animals with streptozo-
tocin-induced diabetes (Krady et al., 2005). The sequence
of retinal modiﬁcations early in DR can therefore be
deduced from the combined results of all these studies:
microglial activation may initially be associated with OP
changes and ERG b/a amplitude ratio reduction; these
modiﬁcations are followed by ganglion cell apoptosis and
subsequent macroglial reaction.
4.2. Diﬀerences between diabetic animal models
There seem to be discrepancies in the sequence of cellu-
lar events in the various diabetic animal models described.
For example, the permeability of the BRB increases as ear-
ly as three to ten days after the induction of diabetes in rats
by streptozotocin injection (Diani et al., 1987). In Ins2 Ati-
ka mice, the BRB was broken down only after 12 weeks of
diabetes, and in our mice with alloxan-induced diabetes,
even this period was not long enough. These diﬀerences
may result from diﬀerences in the techniques used to study
the BRB, or from diﬀerences in the animal strains and spe-
cies (as supported by the ﬁndings of Zhang et al., 2005) or
in the origin of the diabetes, with the BRB seeming to be
much more resistant in diabetic mice than in diabetic rats.
Another main diﬀerence between these animal models
concerns the induction of neuronal apoptosis, principally
in the ganglion cell layer. Ganglion cell apoptosis has been
reported to occur as early as 15 days after the onset of dia-
betes in mice with STZ-induced diabetes (Martin et al.,
2004) and at 1 month in KKAY spontaneous diabeticmice, which also have a triglyceride metabolism disorder
(Ning et al., 2004). In the Ins2 atika mice, apoptotic cells
were detected as four weeks after the onset of diabetes
and the number of cell bodies in the ganglion cell layer
was found to be smaller than in the control after 22 weeks
of diabetes (Barber et al., 2005). By contrast, no ganglion
cell apoptosis was detected in our model of mice with allox-
an-induced diabetes, even after three months. Alloxan and
STZ both trigger pancreatic b-cell necrosis and diabetes:
alloxan does so by creating an oxidative stress whereas
STZ induces DNA alkylation (Szkudelski, 2001). No data
are available concerning the relative toxicities of these two
drugs to the mouse retina. However, the reported STZ-in-
duced ganglion cell death is unlikely to be due to a direct
toxic eﬀect on the retina, for two reasons. Firstly, Asnaghi
et al. (2003) reported an absence of glial reactions and gan-
glion cell apoptosis in mice with STZ-induced diabetes,
three months after the induction of diabetes (Asnaghi
et al., 2003). Secondly, insulin injection can reduce the
number of apoptotic ganglion cells in rats with STZ-in-
duced diabetes (Barber et al., 1998).
The absence of ganglion cell apoptosis in our study and
in that by Asnaghi et al. (2003) may result from neuropro-
tective eﬀects of insulin. In both these studies, the diabetic
mice received regular insulin injections, whereas, in other
studies reporting ganglion cell apoptosis, the diabetic mice
received no insulin (Asnaghi et al., 2003; Barber et al.,
1998; Martin et al., 2004; Ning et al., 2004; Park et al.,
2003). Insulin is classically administered to normalise blood
glucose levels, to prevent complications due to hyperglyca-
emia. In rats with STZ-induced diabetes, insulin injections
can restore normal glycaemia and limit the number of
apoptotic ganglion cells (Barber et al., 1998). In our study,
the ganglion cell survival cannot be attributed to insulin-
mediated control over glycaemia, because blood glucose
levels were not normalised by insulin injections during
the study period. Insulin was administered to prevent the
rapid death of untreated animals. Similarly, insulin has
been shown to mediate the neuroprotection of ganglion
cells in rats with STZ-induced diabetes, despite incomplete
control of hyperglycaemia (Asnaghi et al., 2003). Insulin
neuroprotection has also been reported in cultured R28 ret-
inal neurons, following serum deprivation (Wu et al.,
2004). The injection of insulin into mice with alloxan- or
STZ-induced diabetes may, thus, also provide neuroprotec-
tion for ganglion cells.
5. Conclusion
In summary, we report here the absence of neuronal
apoptosis three months after the induction of diabetes by
alloxan injection in mice. By contrast, the microglial chang-
es and electroretinographic alterations reported in other
models of DR were observed. In future studies, we will
investigate whether this early inﬂammatory response can
trigger ganglion cell death and the macroglial reaction in
animals with DR.
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